Physician profile
Nelson Kanter
NPI 1750389490
$1,842.41
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $457 · 2021: $348 · 2022: $300.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $574.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $333.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $185.24 | 2019-2022 | |
| Genentech USA, INC. | $140.18 | 2019-2020 | |
| Electromed, INC. | $84.54 | 2019-2022 | |
| Mylan Specialty L.P. | $74.92 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $38.27 | 2019-2022 | |
| Insmed, INC. | $35.81 | 2019-2021 | |
| Resmed Corp | $27.14 | 2019 | |
| Sunovion Pharmaceuticals INC. | $25.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.52 | 2022 | |
| Philips North America LLC | $18.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.81 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13.40 | 2022 | |
| Grifols USA, LLC | $12.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Kanter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.